TP53 or Not TP53: That is the Question.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Azacitidine and venetoclax is a standard frontline regimen for newly diagnosed unfit AML patients. In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics do not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.

Keyphrases

newly diagnosed
acute myeloid leukemia
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
study protocol
patient reported
double blind
placebo controlled